Month: June 2021

How I Found My Mission

In Sponsored ContentJune 30, 2021510 Views

Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly

In Federal, Judicial, RegulatoryJune 29, 20211388 Views

Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.

On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.

At least

…

DOJ Says Lilly and Novo Nordisk’s 340B Actions Cost Providers Over $125 Million a Month and Hurt Patients

In Federal, JudicialJune 29, 2021401 Views

Tom Mirga

Lilly and Novo Nordisk's denials of 340B drug discounts when covered entities use contract pharmacies are each causing entities to lose more than $62 million per month on average in 340B program savings, the government says.

Drug manufacturers Eli Lilly and Novo Nordisk’s denials of 340B drug discounts when covered entities use contract pharmacies are causing entities to lose more than a combined total of $125 million per month in 340B program savings, federal

…

CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program

In Federal, RegulatoryJune 29, 2021323 Views

Ron Shinkman

Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record

…

NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month

In Federal, RegulatoryJune 24, 2021372 Views

Tom Mirga

President Biden has yet to select a new leader for the Health Resources and Services Administration, the federal agency responsible for the 340B drug pricing program.

Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.

This normally might

…

Recent Supreme Court Ruling Frees States to Stop PBMs’ 340B Two-Tier Pricing, Health Care Lawyers Say

In Research/ReportsJune 24, 2021684 Views

Ron Shinkman

A recent Supreme Court decision was a big win for 340B providers, K&L Gates partners (left to right) Don Walker, Leah D’Aurora Richardson, and Victoria Hamscho say in a new American Health Law Association paper.

A recent U.S. Supreme Court decision is spurring more states to enact laws banning pharmacy benefit managers (PBMs) from reimbursing 340B pharmacies less for prescription drugs than non-340B providers, health care lawyers say in a new paper.

According

…

340B Report Publisher and CEO Examines Four Burning Questions in Contract Pharmacy Standoff

In Other IndustryJune 24, 2021283 Views

Tom Mirga

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four questions that need to be addressed in the contract pharmacy standoff.

In his latest column for Omnicell, 340B Report Publisher and CEO Ted Slafsky ponders four burning questions as we approach the first anniversary of drug manufacturers stopping or placing restrictions on 340B drug discounts in the contract pharmacy

…

HRSA’s Order for 340B is a Win for Rural Accountable Care

In Sponsored ContentJune 24, 2021737 Views

News Alert: Becerra Puts His Imprint On Long-Awaited 340B Dispute Resolution Board

In Federal, RegulatoryJune 23, 20211103 Views

Ted Slafsky

HHS Secretary Xavier Becerra made appointments today to the 340B administrative dispute resolution board. | Shutterstock

U.S. Health and Human Services (HHS) Secretary Xavier Becerra this morning announced his six appointees to the long-awaited 340B administrative dispute resolution (ADR) board.

The move will be welcomed by the 340B provider community, which has pushed for

…

Pharma’s 340B Contract Pharmacy Limits Are Costing Providers $3.2 Billion a Year, DOJ Tells Court

In Federal, JudicialJune 22, 2021627 Views

Tom Mirga

Covered entities' monthly 340B savings on Sanofi products dropped from $54.2 million just before the company limited discounts on drugs shipped to contract pharmacies to about $5 million within two months, federal lawyers told a judge last week.

Hospitals, health centers, and clinics are losing a projected $3.2 billion a year in 340B program savings due to six drug manufacturers’ denials of 340B pricing on drugs shipped to contract pharmacies, the federal government said in a

…